Last reviewed · How we verify
Placebo for Lofexidine
A placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect.
A placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect. Used for Control arm in clinical trials for opioid withdrawal management (comparator to lofexidine).
At a glance
| Generic name | Placebo for Lofexidine |
|---|---|
| Sponsor | Institute of Mental Health, Singapore |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
Placebos are inert substances used as controls in clinical trials or, in some cases, as therapeutic interventions that rely on patient expectation and psychological mechanisms. In this context, it serves as a comparator to lofexidine, an alpha-2 adrenergic agonist used in opioid withdrawal management. The placebo arm allows assessment of lofexidine's efficacy independent of expectation effects.
Approved indications
- Control arm in clinical trials for opioid withdrawal management (comparator to lofexidine)
Common side effects
Key clinical trials
- Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal (PHASE2)
- An Innovative Intervention for OUD Treatment (PHASE2, PHASE3)
- Sublingual Dexmedetomidine for Treating Opioid Withdrawal (PHASE1, PHASE2)
- Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder (NA)
- Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans (PHASE2)
- Impact of Lofexidine on Stress, Craving and Opioid Use (PHASE2)
- Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal (PHASE2)
- Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Lofexidine CI brief — competitive landscape report
- Placebo for Lofexidine updates RSS · CI watch RSS
- Institute of Mental Health, Singapore portfolio CI